written on 28.04.2014

Experts foresee premium pricing for overdose-fighting injector Evzio


Amid fierce debate over hepatitis C drug costs, another example of potentially questionable pricing looms, <em>The New York Times</em> contends. The new anti-overdose injector, Evzio, is as-yet unpriced, but it could well follow in the footsteps of other newly approved–and newly pricey–formulations of long-off-patent meds.